New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer’s Disease

A series of new tetrahydroacridine and 3,5-dichlorobenzoic acid hybrids with different spacers were designed, synthesized, and evaluated for their ability to inhibit both cholinesterase enzymes. Compounds <b>3a</b>, <b>3b</b>, <b>3f</b>, and <b>3g</b>...

Full description

Bibliographic Details
Main Authors: Kamila Czarnecka, Małgorzata Girek, Przemysław Wójtowicz, Paweł Kręcisz, Robert Skibiński, Jakub Jończyk, Kamil Łątka, Marek Bajda, Anna Walczak, Grzegorz Galita, Jacek Kabziński, Ireneusz Majsterek, Piotr Szymczyk, Paweł Szymański
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/21/11/3765
id doaj-e31425d6c23c4996a96f2fb20d8acfc8
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Kamila Czarnecka
Małgorzata Girek
Przemysław Wójtowicz
Paweł Kręcisz
Robert Skibiński
Jakub Jończyk
Kamil Łątka
Marek Bajda
Anna Walczak
Grzegorz Galita
Jacek Kabziński
Ireneusz Majsterek
Piotr Szymczyk
Paweł Szymański
spellingShingle Kamila Czarnecka
Małgorzata Girek
Przemysław Wójtowicz
Paweł Kręcisz
Robert Skibiński
Jakub Jończyk
Kamil Łątka
Marek Bajda
Anna Walczak
Grzegorz Galita
Jacek Kabziński
Ireneusz Majsterek
Piotr Szymczyk
Paweł Szymański
New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer’s Disease
International Journal of Molecular Sciences
acetylcholinesterase inhibitors
Alzheimer’s disease
molecular modeling
Ellman’s method
author_facet Kamila Czarnecka
Małgorzata Girek
Przemysław Wójtowicz
Paweł Kręcisz
Robert Skibiński
Jakub Jończyk
Kamil Łątka
Marek Bajda
Anna Walczak
Grzegorz Galita
Jacek Kabziński
Ireneusz Majsterek
Piotr Szymczyk
Paweł Szymański
author_sort Kamila Czarnecka
title New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer’s Disease
title_short New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer’s Disease
title_full New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer’s Disease
title_fullStr New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer’s Disease
title_full_unstemmed New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer’s Disease
title_sort new tetrahydroacridine hybrids with dichlorobenzoic acid moiety demonstrating multifunctional potential for the treatment of alzheimer’s disease
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1661-6596
1422-0067
publishDate 2020-05-01
description A series of new tetrahydroacridine and 3,5-dichlorobenzoic acid hybrids with different spacers were designed, synthesized, and evaluated for their ability to inhibit both cholinesterase enzymes. Compounds <b>3a</b>, <b>3b</b>, <b>3f</b>, and <b>3g</b> exhibited selective butyrylcholinesterase (<i>Eq</i>BuChE) inhibition with IC<sub>50</sub> values ranging from 24 to 607 nM. Among them, compound 3b was the most active (IC<sub>50</sub> = 24 nM). Additionally, 3c (IC<sub>50</sub> for <i>Ee</i>AChE = 25 nM and IC<sub>50</sub> for <i>Eq</i>BuChE = 123 nM) displayed dual cholinesterase inhibitory activity and was the most active compound against acetylcholinesterase (AChE). Active compound 3c was also tested for the ability to inhibit Aβ aggregation. Theoretical physicochemical properties of the compounds were calculated using ACD Labs Percepta and Chemaxon. A Lineweaver–Burk plot and docking study showed that 3c targeted both the catalytic active site (CAS) and the peripheral anionic site (PAS) of AChE. Moreover, 3c appears to possess neuroprotective activity and could be considered a free-radical scavenger. In addition, 3c did not cause DNA damage and was found to be less toxic than tacrine after oral administration; it also demonstrated little inhibitory activity towards hyaluronidase (HYAL), which may indicate that it possesses anti-inflammatory properties. The screening for new in vivo interactions between 3c and known receptors was realized by yeast three-hybrid technology (Y3H).
topic acetylcholinesterase inhibitors
Alzheimer’s disease
molecular modeling
Ellman’s method
url https://www.mdpi.com/1422-0067/21/11/3765
work_keys_str_mv AT kamilaczarnecka newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease
AT małgorzatagirek newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease
AT przemysławwojtowicz newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease
AT pawełkrecisz newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease
AT robertskibinski newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease
AT jakubjonczyk newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease
AT kamilłatka newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease
AT marekbajda newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease
AT annawalczak newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease
AT grzegorzgalita newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease
AT jacekkabzinski newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease
AT ireneuszmajsterek newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease
AT piotrszymczyk newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease
AT pawełszymanski newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease
_version_ 1724699728201908224
spelling doaj-e31425d6c23c4996a96f2fb20d8acfc82020-11-25T03:00:02ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-05-01213765376510.3390/ijms21113765New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer’s DiseaseKamila Czarnecka0Małgorzata Girek1Przemysław Wójtowicz2Paweł Kręcisz3Robert Skibiński4Jakub Jończyk5Kamil Łątka6Marek Bajda7Anna Walczak8Grzegorz Galita9Jacek Kabziński10Ireneusz Majsterek11Piotr Szymczyk12Paweł Szymański13Department of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, PolandDepartment of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, PolandDepartment of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, PolandDepartment of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, PolandDepartment of Medicinal Chemistry, Faculty of Pharmacy, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, PolandDepartment of Physicochemical Drug Analysis, Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, PolandDepartment of Physicochemical Drug Analysis, Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, PolandDepartment of Physicochemical Drug Analysis, Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, PolandDepartment of Clinical Chemistry and Biochemistry, Medical University of Lodz, Narutowicza 60, 90-647 Lodz, PolandDepartment of Clinical Chemistry and Biochemistry, Medical University of Lodz, Narutowicza 60, 90-647 Lodz, PolandDepartment of Clinical Chemistry and Biochemistry, Medical University of Lodz, Narutowicza 60, 90-647 Lodz, PolandDepartment of Clinical Chemistry and Biochemistry, Medical University of Lodz, Narutowicza 60, 90-647 Lodz, PolandDepartment of Pharmaceutical Biotechnology, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, PolandDepartment of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, PolandA series of new tetrahydroacridine and 3,5-dichlorobenzoic acid hybrids with different spacers were designed, synthesized, and evaluated for their ability to inhibit both cholinesterase enzymes. Compounds <b>3a</b>, <b>3b</b>, <b>3f</b>, and <b>3g</b> exhibited selective butyrylcholinesterase (<i>Eq</i>BuChE) inhibition with IC<sub>50</sub> values ranging from 24 to 607 nM. Among them, compound 3b was the most active (IC<sub>50</sub> = 24 nM). Additionally, 3c (IC<sub>50</sub> for <i>Ee</i>AChE = 25 nM and IC<sub>50</sub> for <i>Eq</i>BuChE = 123 nM) displayed dual cholinesterase inhibitory activity and was the most active compound against acetylcholinesterase (AChE). Active compound 3c was also tested for the ability to inhibit Aβ aggregation. Theoretical physicochemical properties of the compounds were calculated using ACD Labs Percepta and Chemaxon. A Lineweaver–Burk plot and docking study showed that 3c targeted both the catalytic active site (CAS) and the peripheral anionic site (PAS) of AChE. Moreover, 3c appears to possess neuroprotective activity and could be considered a free-radical scavenger. In addition, 3c did not cause DNA damage and was found to be less toxic than tacrine after oral administration; it also demonstrated little inhibitory activity towards hyaluronidase (HYAL), which may indicate that it possesses anti-inflammatory properties. The screening for new in vivo interactions between 3c and known receptors was realized by yeast three-hybrid technology (Y3H).https://www.mdpi.com/1422-0067/21/11/3765acetylcholinesterase inhibitorsAlzheimer’s diseasemolecular modelingEllman’s method